| AC | Aminocaproic acid |
| ACVRL1/ALK1 | Activin Receptor-Like Kinase 1 |
| AVM | Arteriovenous Malformation |
| BMP9 | Bone Morphogenetic Protein 9 |
| BZ | Bevacizumab |
| CM | Capillary Malformation |
| CYP2D6 | Cytochrome P450 2D6 |
| ECs | Endothelial Cells |
| EMA | European Medicine Agency |
| ENG | Endoglin |
| EPHB4 | Ephrin Type-B Receptor 4 |
| ER | Estrogen Receptor |
| ESS | Epistaxis Severity Score |
| FDA | Food and Drug Administration |
| FGF | Fibroblast Growth Factor |
| FK506 | Tacrolimus |
| GI | Gastrointestinal |
| HHT | Hereditary Hemorrhagic Telangiectasia |
| iKO | inducible Knockout |
| JPHT | Juvenile Polyposis/HHT |
| MADH4/Smad4 | Mothers Against Decapentaplegic Homolog 4 |
| mRNA | messenger Ribonucleic Acid |
| NAC | N-acetylcysteine |
| OLT | Orthotopic Liver Transplant |
| OPG | Osteoprotegerin |
| PDGF | Platelet Derived Growth Factor |
| RANK | Receptor Activator of Nuclear Factor κ B |
| RANK-L | Receptor Activator of Nuclear Factor κ B Ligand |
| RASA1 | RAS P21 Protein Activator 1 |
| SERMs | Selective Estrogen Receptor Modulator |
| TA | Tranexamic Acid |
| TFRE | Transcription Factor Regulatory Element |
| TGF-β | Transforming Growth Factor β |
| VEGF | Vascular Endothelial Growth Factor |
| VM | Venous Malformation |